<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        5-5888-25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ADYNOVATE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1504.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Baxalta manufacturing Sarl " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Baxalta manufacturing Sarl 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            TAKEDA PHARMACEUTICALS USA, INC.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B02BD02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ADYNOVATE contains the active substance rurioctocog alfa pegol,<br />pegylated human coagulation factor VIII. The human coagulation<br />factor VIII has been modified to prolong its duration of action.<br />Factor VIII is necessary for the blood to form clots and stop<br />bleedings. In patients with haemophilia A (inborn lack of factor VIII),<br />it is missing or not working properly.<br />ADYNOVATE is used for the treatment and prevention of bleeding<br />in children and adults with haemophilia A (an inherited bleeding<br />disorder caused by lack of factor VIII).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do NOT use Adynovate:<br />Do not attempt to do an infusion to yourself unless you have been<br />taught how by your healthcare provider or hemophilia center.<br />You must carefully follow your healthcare provider&rsquo;s instructions<br />regarding the dose and schedule for infusing ADYNOVATE so that<br />your treatment will work best for you.<br />Who should not use ADYNOVATE?<br />You should not use ADYNOVATE if you:<br />&bull; Are allergic to mice or hamster protein<br />&bull; Are allergic to any ingredients in ADYNOVATE or ADVATE<br />Tell your healthcare provider if you are pregnant or breastfeeding<br />because ADYNOVATE may not be right for you.<br />Warnings and precautions<br />Hypersensitivity Reactions<br />Hypersensitivity reactions are possible with ADYNOVATE.<br />Allergic‑type hypersensitivity reactions, including anaphylaxis, have<br />been reported with other recombinant antihemophilic factor VIII<br />products, including the parent molecule, ADVATE. Early signs of<br />hypersensitivity reactions that can progress to anaphylaxis may<br />include angioedema, chest tightness, dyspnea, wheezing, urticaria,<br />and pruritus. Immediately discontinue administration and initiate<br />appropriate treatment if hypersensitivity reactions occur.<br />Formation of neutralizing antibodies (inhibitors) to factor VIII<br />can occur following administration of ADYNOVATE. Monitor<br />patients regularly for the development of factor VIII inhibitors by<br />appropriate clinical observations and laboratory tests. Perform an<br />assay that measures factor VIII inhibitor concentration if the plasma<br />factor VIII level fails to increase as expected, or if bleeding is not<br />controlled with expected dose.<br />Pregnancy<br />Risk Summary<br />There are no data with ADYNOVATE use in pregnant women to<br />inform a drug-associated risk. Animal reproduction studies have<br />not been conducted with ADYNOVATE. It is unknown whether<br />ADYNOVATE can cause fetal harm when administered to a<br />pregnant woman or can affect reproduction capacity. DYNOVATE<br />should be given to a pregnant woman only if clearly needed. In the<br />U.S. general population, the estimated background risk of major<br />birth defect and miscarriage in clinically recognized pregnancies is<br />2-4% and 15-20%, respectively.<br />Lactation<br />Risk Summary<br />There is no information regarding the presence of ADYNOVATE<br />in human milk, the effect on the breastfed infant, or the effects<br />on milk production. The developmental and health benefits of<br />breastfeeding should be considered along with the mother&rsquo;s<br />clinical need for ADYNOVATE and any potential adverse effects<br />on the breastfed infant from ADYNOVATE or from the underlying<br />maternal condition.<br />Pediatric Use<br />Safety and efficacy studies have been performed in 91 previously<br />treated, pediatric patients age 1 year to &lt;18 years who received<br />at least one dose of ADYNOVATE as part of routine prophylaxis,<br />on-demand treatment of bleeding episodes, or perioperative<br />management.<br />Adolescent subjects age 12 to &lt;18 (n=25) were enrolled in<br />the adult and adolescent safety and efficacy trial, and subjects<br />&lt;12 years of age (n=66) were enrolled in a pediatric trial. The<br />safety and efficacy of ADYNOVATE in routine prophylaxis and<br />the treatment of bleeding episodes were comparable between<br />children and adults. Pharmacokinetic studies in children (&lt;12 years)<br />have demonstrated higher clearance, a shorter half-life and lower<br />incremental recovery of factor VIII compared to adults. Because<br />clearance (based on per kg body weight) has been demonstrated<br />to be higher in children (&lt;12 years), dose adjustment or more<br />frequent dosing based on per kg body weight may be needed in<br />this population. [see Clinical Pharmacology (12.3)]<br />Geriatric Use<br />Clinical studies of ADYNOVATE did not include subjects aged<br />65 and over.<br />Interactions with Other Medicinal Products and Other Forms of<br />Interaction<br />No interaction studies have been performed with ADYNOVATE.<br />Fertility<br />Long-term studies in animals to evaluate the carcinogenic potential<br />of ADYNOVATE or studies to determine the effects of ADYNOVATE<br />on genotoxicity or fertility have not been performed.<br />Effects on Ability to Drive and Use Machines There is no<br />information on the effects of ADYNOVATE on the ability to drive or<br />operate an automobile or other heavy machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Treatment with ADYNOVTE will be started and supervised<br />by a doctor who is experienced in the care of patients with<br />haemophilia A.<br />Your doctor will calculate your dose of ADYNOVITE depending<br />on your condition and body weight, and on whether it is used<br />for prevention or treatment of bleeding. The frequency of<br />administration will depend on how well ADYNOVATE is working<br />for you. Usually, the replacement therapy with ADYNOVATE is a<br />life‑long treatment.<br />Always use this medicine exactly as your doctor has told you.<br />Check with your doctor if you are not sure.<br />Prevention of bleeding<br />The usual dose of ADYNOVATE is 40 to 50 IU per kg body weight,<br />administered 2 times per week.<br />Treatment of bleeding<br />The dose of ADYNOVATE is calculated depending on your body<br />weight and the factor VIII levels to be achieved. The target factor<br />VIII levels will depend on the severity and location of the bleeding.<br />If you think that the effect of ADYNOVATE is insufficient, talk to<br />your doctor.<br />Your doctor will perform appropriate laboratory tests to make<br />sure that you have adequate factor VIII levels. This is particularly<br />important if you are having major surgery.<br />Use in children and adolescents<br />ADYNOVATE can be used only in adolescents and adults. The dose<br />in adolescents is also calculated to body weight and is the same<br />dose as for adults.<br />How ADYNOVATE is given<br />ADYNOVATE is usually injected into a vein (intravenously) by your<br />doctor or nurse. You or someone else might also administer<br />ADYNOVATE as an injection, but only after receiving adequate<br />training. Detailed instructions for self-administration are given at<br />the end of this package leaflet.<br />If you use more ADYNOVATE than you should<br />Always use ADYNOVATE exactly as your doctor has told you. You<br />should check with your doctor if you are not sure. If you inject<br />more ADYNOVATE than recommended, tell your doctor as soon as<br />possible.<br />If you forget to use ADYNOVATE<br />Do not inject a double dose to make up for a forgotten dose.<br />Proceed with the next injection as scheduled and continue as<br />advised by your doctor.<br />If you stop using ADYNOVATE<br />Do not stop using ADYNOVATE without consulting your doctor.<br />Proceed with the next injection as scheduled and continue as<br />advised by your doctor.<br />If you have any further questions on the use of this medicine, ask<br />your doctor.<br />1. Prepare a clean flat surface and gather all the materials you will<br />need for the infusion.<br />&bull; Check the expiration date, and let the vials with the ADYNOVATE<br />concentrate and the Sterile Water for Injection, USP (diluent)<br />warm up to room temperature.<br />&bull; Wash your hands and put on clean exam gloves. If infusing<br />yourself at home, the use of gloves is optional.<br />&bull; If you are using more than one vial of ADYNOVATE, make sure<br />you mix each vial of ADYNOVATE with the Sterile Water for<br />Injection, USP that is provided in the box.<br />&bull; Inspect the contents of the product and diluent vials. The<br />ADYNOVATE powder should be white to off-white in colour<br />and the diluent should not contain particles. Do not use if<br />discoloration or particles are seen.<br />2. Remove caps from the ADYNOVATE concentrate and diluent vials<br />to expose the centres of the rubber stoppers.<br />3. Disinfect the stoppers with a sterile alcohol prep pad (or other<br />suitable solution suggested by your healthcare provider or<br />hemophilia center) by rubbing the stoppers firmly for several<br />seconds and allow them to dry prior to use. Place the vials on a flat<br />surface.<br />4. Open the BAXJECT II Hi-Flow device package by completely<br />peeling away the lid, without touching the inside of the package.<br />Do not remove the BAXJECT II Hi-flow device from the package.<br />5. Turn the package with the BAXJECT II Hi-Flow device upside<br />down and place it over the top of the diluent vial. Fully insert the<br />clear plastic spike of the device into the center of the diluent vial&rsquo;s<br />stopper by pushing straight down. Grip the package at its edge and<br />lift it off the device. Be careful not to touch the purple plastic spike.<br />Do not remove the blue cap from the BAXJECT II Hi-Flow device.<br />The diluent vial now has the BAXJECT II Hi-Flow device connected<br />to it and is ready to be connected to the ADYNOVATE vial.<br />6. To connect the diluent vial to the ADYNOVATE vial, turn<br />the diluent vial over and place it on top of the vial containing<br />ADYNOVATE concentrate. Fully insert the purple plastic spike into<br />the ADYNOVATE vial&rsquo;s stopper by pushing straight down. Diluent<br />will flow into the ADYNOVATE vial. This should be done right away<br />to keep the liquid free of germs.<br />7. Swirl the connected vials gently and continuously until the<br />ADYNOVATE is completely dissolved. Do not shake.<br />8. Take off the blue cap from the BAXJECT II Hi-Flow device and<br />connect the syringe. Use of a Luer-lock syringe is recommended.<br />Be careful to not inject air.<br />1<br />2<br />9. Turn over the connected vials so that the ADYNOVATE vial is<br />on top. Draw the ADYNOVATE solution into the syringe by pulling<br />back the plunger slowly. Disconnect the syringe from the vials.<br />Attach the infusion needle to the syringe using a winged (butterfly)<br />infusion set, if available. Point the needle up and remove any<br />air bubbles by gently tapping the syringe with your finger and<br />slowly and carefully pushing air out of the syringe and needle. The<br />ADYNOVATE solution should look clear and colorless. If not, do not<br />use it and notify Baxalta immediately.<br />10. If you are using more than one vial of ADYNOVATE, the<br />contents of more than one vial may be drawn into the same<br />syringe (Following Steps 1-9). You will need a separate BAXJECT II<br />Hi‑Flow device to mix each additional vial of ADYNOVATE. Apply<br />a tourniquet and get the injection site ready by wiping the skin<br />well with a sterile alcohol prep pad (or other suitable solution<br />suggested by your healthcare provider or hemophilia center).<br />11. Insert the needle into the vein and remove the tourniquet.<br />Slowly infuse the ADYNOVATE. Do not infuse any faster than<br />10 mL per minute.<br />12. Take the needle out of the vein and use sterile gauze to put<br />pressure on the infusion site for several minutes.<br />13. Do not recap the needle. Place it with the used syringe in a<br />hard-walled Sharps container for proper disposal.<br />14. Remove the peel-off label from the ADYNOVATE vial and place<br />it in your logbook. Clean any spilled blood with a freshly prepared<br />mixture of 1 part bleach and 9 parts water, soap and water, or any<br />household disinfecting solution.<br />15. Dispose of the used vials and BAXJECT II Hi-Flow device in your<br />hard-walled sharps container without taking them apart. Do not<br />dispose of these supplies in ordinary household trash.<br />What are the ADYNOVATE dosage strengths?<br />Method and route of administration<br />For intravenous use after reconstitution only<br />Administration<br />&bull; Visually inspect the reconstituted ADYNOVATE solution for<br />particulate matter and discoloration prior to administration,<br />whenever solution and container permit. The final ADYNOVATE<br />solution should be clear and colorless.<br />Do not use if particulate matter or discoloration is observed.<br />&bull; Administer ADYNOVATE as soon as possible, but no later than<br />3 hours after reconstitution.<br />&bull; One unit per kilogram body weight will raise the factor VIII level<br />by 2% international units per deciliter (IU per dL). Each vial of<br />ADYNOVATE is labeled with the actual amount of recombinant<br />factor VIII present in IU. (2.1)<br />&bull; On-demand treatment and control of bleeding episodes and<br />perioperative management:<br />n Estimated Increment of factor VIII (IU/dL or % of normal) =<br />[Total Dose (IU)/body weight (kg)] x 2 (IU/dL per IU/kg)<br />n Dose (IU) = Body Weight (kg) x Desired factor VIII Rise<br />(IU/dL or % of Normal) x 0.5 (IU/kg per IU/dL)<br />&bull; Routine prophylaxis: Administer 40-50 IU per kg body weight<br />2 times a week (Starting dose of 55 IU per kg body weight<br />2 times a week patients &lt;12 years of age with a maximum of<br />70 IU per kg).<br />&bull; Inject intravenously over a period of less than or equal to<br />5 minutes (maximum infusion rate of 10 mL per min). (2.3)<br />If you use more Adynovate than you should<br />If you think that you used more Adynovate than you should, speak<br />to your doctor as soon as possible.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You can have an allergic reaction to ADYNOVATE. Call your<br />healthcare provider right away and stop treatment if you get a rash<br />or hives, itching, tightness of the throat, chest pain or tightness,<br />difficulty breathing, lightheadedness, dizziness, nausea or fainting.<br />The common side effects of ADYNOVATE are headache and nausea.<br />Tell your healthcare provider about any side effects that bother you<br />or do not go away.<br />These are not all the possible side effects with ADYNOVATE. You<br />can ask your healthcare provider for information that is written for<br />healthcare professionals.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not freeze.<br />&bull; Store at refrigerated temperature 2&deg;C to 8&deg;C<br />&bull; May store at room temperature not to exceed 30&deg;C for up to<br />3 months.<br />o Write the date on the carton when ADYNOVATE is removed<br />from refrigeration.<br />o After storage at room temperature, do not return product<br />back to the refrigerator.<br />&bull; Do not use beyond the expiration date printed on the carton<br />or vial.<br />&bull; Store ADYNOVATE in the original box and protect from extreme<br />exposure to light.<br />&bull; Reconstituted/diluted solution: should be administered at<br />room temperature not more than 3 hours after reconstitution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. What Adynovate contains<br />- Active substance is Antihemophilic Factor (Recombinant),<br />PEGylated<br />- The other ingredient are: Tris, mannitol, trehalose, glutathione,<br />and/or polysorbate 80<br />- Solvent is sterile water<br />ADYNOVATE with 5 mL Sterile Water for Injection in a<br />BAXJECT III system comes in seven different dosage strengths:<br />250 International Units (IU), 500 IU, 750 IU and 1000 IU. The<br />actual strength will be imprinted on the label and on the box. The<br />seven different strengths are color coded, as follows:<br />Each vial of ADYNOVATE is labeled with the AHF activity expressed<br />in IU per vial.<br />Light<br />Blue<br />Dosage strength of approximately 250 International<br />Units per vial<br />Pink Dosage strength of approximately 500 International<br />Units per vial<br />Light<br />Green<br />Dosage strength of approximately 1000 International<br />Units per vial</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sterile, nonpyrogenic, white to off-white powder. Reconstituted
ADYNOVATE should be clear, colourless, and free from foreign
particles.
Not all presentations may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Baxalta US Inc.<br />A wholly owned subsidiary of<br />Takeda Pharmaceutical Company Limited.<br />300 Shire way, Lexington, MA 02421, USA<br />Tel: + 1 617-349-0200</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in
Sep. 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&rdquo;rurioctocog alfa pegol&ldquo; يحتوي أدينوفيت على المادة الفعالة ريركتوكوغ ألفا بيجول<br />وبلمرة البولي إيثيلين غليكول لعامل التجلط البشري الثامن. تم تعديل عامل التجلط البشري<br />الثامن لإطالة مدة مفعوله. العامل الثامن ضروري لتمكين الدم من تكوين تجلطات لإيقاف<br />النزيف. لدى المرضى المصابين بالهيموفيليا أ )نقص العامل الثامن منذ الولادة(، فإنه<br />يكون مفقودًا أو لا يعمل بالشكل الصحيح.<br />يُستخدم أدينوفيت في علاج النزيف والوقاية منه لدى الأطفال والبالغين المصابين<br />بالهيموفيليا أ )اضطراب وراثي في النزيف ناتج عن نقص العامل الثامن(.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تحاول إعطاء الحقنة لنفسك، ما لم يخبرك مقدم الرعاية الصحية أو مركز<br />الهيموفيليا بكيفية القيام بذلك.<br />يجب اتباع تعليمات مقدم الرعاية الصحية بعناية بخصوص الجرعات وجدول<br />التسريب لأدينوفيت حتى يفيدك العلاج بشكل أفضل.<br />من يحظر عليه استخدام أدينوفيت ؟<br />يحظر عليك استخدام أدينوفيت في حالة:<br />&bull;كنت تعاني من حساسية من الفئران أو بروتينات الهامستر<br />&bull;كنت تعاني من حساسية تجاه أيٍ من مكونات أدينوفيت أو أدفيت<br />أخبري مقدم الرعاية الصحية في حال كنتِ حاملاً أو مرضعًا؛ إذ قد لا يتناسب<br />أدينوفيت معكِ.<br />تحذيرات واحتياطات لتفاعلات فرط<br />الحساسية<br />من الممكن حدوث تفاعلات فرط الحساسية عند استخدام أدينوفيت. تتضمن تفاعلات<br />حساسية نتيجةً لفرط الحساسية، التأق والذي تم الإبلاغ بحدوثه مع مأشوب عامل<br />مضاد الناعور لمنتجات العامل الثامن وتشمل الجزيء الأساسي وأدفيت. العلامات<br />المبكرة لتفاعلات فرط الحساسية التي يمكن أن تتطور إلى التأق والذي قد يتضمن<br />الوذمة الوعائية وضيق الصدر وضيق التنفس والأزيز والشرى والحكة الشديدة.<br />ينبغي التوقف عن تناول الدواء فورًا وبدء العلاج المناسب في حالة حدوث تفاعلات<br />فرط الحساسية.<br />قد يحدث تكوين لأجسام مضادة )المثبطات( للعامل الثامن بعد تناول أدينوفيت. مراقبة<br />المرضى بانتظام لمعرفة مدى تطور مثبطات العامل الثامن من خلال الملاحظات<br />السريرية المناسبة والاختبارات المعملية. عمل مقايسة لقياس مدى تركيز مثبط العامل<br />الثامن، وفي حال فشل مستوى العامل الثامن في البلازما في الازدياد كما هو متوقع، أو<br />لم يتم السيطرة على النزيف بالجرعة المتوقعة.<br />الحمل<br />موجز المخاطر<br />لا تتوفر بيانات متاحة بخصوص استخدام أدينوفيت من قبل السيدات الحوامل لمعرفة<br />أي مخاطر تنجم عنه. لم تُجرَ دراسات تكاثر على الحيوانات باستخدام أدينوفيت. من<br />غير المعروف أيضًا إذا ما كان يمكن أن يتسبب أدينوفيت في ضررٍ على الجنين عند<br />إعطائه للمرأة الحامل أو هل يمكنه التأثير في القدرة على الإنجاب. لا ينبغي إعطاء<br />أدينوفيت للمرأة الحامل إلا إذا كانت تحتاجه احتياجًا ضروريًا. في الفئة الأمريكية<br />العامة للمرضى، يُعد الخطر التقديري الأساسي وسقوط الحمل في حالات الحمل<br />20 %، على التوالي. - المشخصة سريريًا 24 % و 15<br />الرضاعة<br />موجز المخاطر<br />لا تتوفر معلومات بشأن وجود أدينوفيت في لبن الأم، أو على تأثيره في الرضّع الذين<br />يرضعون طبيعيًا من الثدي، أو على تأثيره على إفراز الحليب. يجب الوضع في<br />الاعتبار الفوائد التي تعود على الصحة والنمو نتيجة الرضاعة الطبيعية، بالإضافة<br />إلى حاجة الأم السريرية إلى أدينوفيت وأي آثار جانبية محتملة لأدينوفيت على الطفل<br />الذي يرضع طبيعيًا، أو من الحالة الكامنة للأم.<br />الاستخدام مع الأطفال<br />أجريت دراسات السلامة والفاعلية في 91 حالة من الحالات التي تلقت علاجًا في<br />السابق من الأطفال المرضى والذين تتراوح أعمارهم بين عامٍ ومن هم أقل من 18<br />عامًا والذين تلقوا جرعة واحدة على الأقل من عقار أدينوفيت كجزء من علاج الوقاية<br />الروتيني أو العلاج حسب الطلب لنوبات النزيف أو إدارة الفترة المحيطة بالجراحة.<br />تم انضمام مراهقين ممن تتراوح أعمارهم بين 12 عامًا إلى من هم دون 18 عامًا<br />)وعددهم = 25 ( في تجربة السلامة والفعالية للبالغين، وتم انضمام الأطفال ممن<br />تتراوح أعمارهم أقل من 12 عامًا في تجربة الأطفال )وعددهم = 66 (.سلامة<br />عقار أدينوفيت وفعاليته في علاج الوقاية الروتينية وعلاج نوبات النزيف كانا قابلين<br />للمقارنة بين الأطفال والبالغين.<br />وقد أظهرت دراسات الحرائك الدوائية للأطفال )ممن هم أقل من 12 عامًا( وجود<br />تصفية أعلى وعمر نصفي أقصر<br />وتعافٍ تزايدي أقل للعامل الثامن مقارنةً بالبالغين. لأن التصفية )على أساس كل كجم<br />من وزن الجسم( تكون أعلى لدى الأطفال )أقل من 12 عامًا(، وقد تكون هناك حاجة<br />إلى تعديل الجرعة أو تكرار الجرعة بشكل أكثر وذلك على أساس كل كجم من وزن<br />]) جسم قد تحتاجه هذه الفئات. ]انظر التركيبة السريرية للدواء ) 12.3<br />الاستخدام مع كبار السن<br />لا تتضمن الدراسات السريرية حول أدينوفيت خضوع من يبلغون من العمر 65<br />عامًا فأكثر.<br />التفاعلات مع المنتجات الدوائية الأخرى وأشكال التفاعل الأخرى<br />لم تُجرَ أي دراسات تفاعل باستخدام أدينوفيت.<br />الخصوبة<br />لم تُجرَ دراسات طويلة الأمد على الحيوانات لتقويم مدى إمكانية تسبب أدينوفيت في<br />الإصابة بالسرطان أو عمل دراسات لتحديد تأثير أدينوفيت على السمية الوراثية أو<br />الخصوبة.<br />تأثير على القدرة على القيادة واستخدام الآلات لا تتوفر معلومات حول تأثير<br />أدينوفيت في القدرة على القيادة أو تشغيل السيارة أو أي معدات ثقيلة أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سيبدأ العلاج باستخدام أدينوفيت وكذلك الإشراف عليه من طبيبٍ خبير في رعاية<br />المصابين بالهيموفيليا ب.<br />سيحسب طبيبك جرعتك من أدينوفيت استنادًا إلى حالتك ووزن جسمك وما إذا كان<br />يُستخدم للوقاية من النزيف أو لعلاجه. سيعتمد تكرار استخدام أدينوفيت على مدى<br />كفاءة عمله معك. وفي الغالب يستمر العلاج البديل من أدينوفيت طوال الحياة.<br />احرص دومًا على استخدام هذا الدواء تمامًا كما أخبرك طبيبك. استشر طبيبك إذا لم<br />تكن متأكدًا.<br />الوقاية من النزيف<br />تتراوح الجرعة المعتادة من أدينوفيت بين 40 إلى 50 وحدة دولية لكل كجم من<br />وزن الجسم، ويتم حقنها مرتين في الأسبوع.<br />علاج النزيف<br />يتم احتساب جرعة أدينوفيت على حسب وزن جسمك ومستويات العامل الثامن<br />المطلوب تحقيقها. ستعتمد المستويات المستهدفة من العامل الثامن على حدة النزيف<br />وموقعه.<br />إذا كان لديك انطباع بأن تأثير أدينوفيت غير كافٍ، فتحدث مع طبيبك.<br />سيُجري الطبيب الاختبارات المعملية الملائمة للتأكد من أن لديك مستويات كافية من<br />العامل الثامن. وهذا له أهمية كبيرة لا سيما إذا كنت ستخضع لجراحة كبيرة.<br />الاستخدام مع الأطفال والمراهقين<br />يمكن استخدام أدينوفيت فقط من قبل المراهقين والبالغين. يتم احتساب الجرعة لدى<br />المراهقين على حسب وزن الجسم وهي نفس الجرعة للبالغين.<br />كيف يتم إعطاء أدينوفيت<br />يحقن الطبيب أو الممرضة في الغالب أدينوفيت في الوريد )وريديًا(. وقد تُعطى أنت<br />أو شخص آخر أيضًا أدينوفيت كحقن، لكن بعد الحصول على تدريب كافٍ فقط.<br />يتم تقديم تعليمات تفصيلية للحقن الذاتي في نهاية نشرة هذه العبوة.<br />في حالة استخدام جرعة أكبر مما ينبغي من أدينوفيت<br />احرص دومًا على استخدام أدينوفيت تمامًا كما أخبرك طبيبك. يجب استشارة الطبيب<br />إذا لم تكن متأكدًا. في حال حقنك جرعة أدينوفيت أكبر من الموصى بها، أبلغ طبيبك<br />في أسرع وقت ممكن.<br />إذا نسيت تناول أدينوفيت<br />لا تحقن جرعة مزدوجة لتعويض الجرعة المنسية. واصل تناول الجرعة التالية<br />حسب المخطط وواصل كما ينصح طبيبك.<br />إذا توقفت عن تناول أدينوفيت<br />لا تتوقف عن استخدام أدينوفيت دون استشارة طبيبك. واصل تناول الجرعة التالية<br />حسب المخطط وواصل كما ينصح طبيبك.<br />إذا كانت لديك أي أسئلة إضافية عن استخدام هذا الدواء، فاسأل طبيبك.<br />1 .1 أعدّ سطحًا مستويًا نظيفًا وقم بتجميع كل المواد التي ستحتاجها للتسريب.<br />&bull;تحقق من تاريخ انتهاء الصلاحية واترك القنينات بعقار أدينوفيت المركز والماء<br />المعقم اللازم للحقن ودستور الأدوية الأمريكي، ويسخن المحلول )المخفف(<br />ليصل لدرجة حرارة الغرفة.<br />&bull;اغسل يديك وارتدِ قفازات فحص نظيفة. في حال أعطيت الحقنة لنفسك في<br />المنزل، فارتداء القفازات اختياري.<br />&bull;إذا كنت تستخدم أكثر من قنينة واحدة من أدينوفيت، فتأكد من خلط كل قنينة<br />منها مع المياه المعقمة للحقن، وأن دستور الأدوية الأمريكي موجود في العلبة.<br />&bull;افحص محتويات المنتج والقنينات المخففة. يجب أن يكون لون مسحوق<br />أدينوفيت من أبيض إلى أبيض مائل للصفرة، ويجب ألا تحتوي المادة المخففة<br />على جسيمات. لا تستخدمه في حال وجدت تغيرًا في اللون أو جسيمات.<br />2 .2 أزِل الأغطية الواقية من أدينوفيت المركز والقنينة المخففة للكشف عن مراكز<br />السدادات المطاطية.<br />3 .3 طهِّر السدادات باستخدام مسحة تحضير كحولية معقمة )أو أي محلول مناسب<br />آخر يقترحه مقدم الرعاية الصحية أو مركز الهيموفيليا( عن طريق فرك<br />السدادات بإحكام لعدة ثوان والسماح لها بالجفاف قبل الاستخدام. ضع القنينات<br />على سطحٍ مستوٍ.<br />من خلال إزالة الغطاء بالكامل &rdquo;BAXJECT II Hi-Flow&ldquo; 4 .4 افتح عبوة جهاز<br />دون لمس الجزء الداخلي من العبوة. لا تُخرج الجهاز من العبوة.<br />5 .5 اقلب العبوة من خلال الجهاز، وضَعْها أعلى القنينة المخففة.أدخِل المسمار<br />البلاستيكي الشفاف للجهاز في مركز سدادة القنينة المخففة عن طريق دفعه<br />لأسفل.<br />أمسِك العبوة من حافتها، وارفعها عن الجهاز. كن حذرًا، ولا تلمس المسمار<br />BAXJECT II البلاستيكي الأرجواني. لا تخلع الغطاء الواقي الأزرق عن جهاز<br />الآن متصلاً بالقنينة المخففة BAXJECT II Hi-Flow أصبح جهاز . Hi-Flow<br />وجاهزًا للتوصيل بقنينة أدينوفيت.<br />6 .6 لتوصيل القنينة المخففة إلى قنينة أدينوفيت، اقلب القنينة المخففة، وضَعها أعلى<br />القنينة التي تحتوي على أدينوفيت المركز. أدِخِل المسمار البلاستيكي الأرجواني<br />في سدادة قنينة أدينوفيت بدفعِه إلى أسفل. سيتدفق محتوى القنينة المخففة إلى<br />قنينة أدينوفيت. يجب القيام بذلك في الحال لحماية السائل من الجراثيم.<br />7 .7 هز القنينة المتصلة برفق وبشكل مستمر حتى يذوب أدينوفيت تمامًا. لا ترجّ<br />الدواء.<br />وصِل BAXJECT II Hi-Flow 8 .8 انزع الغطاء الواقي الأزرق من جهاز<br />المحقنة. يوصى باستخدام محقن عازل للتسرب. كن حذرًا حتى لا تحقن هواء.<br />1<br />2<br />9 .9 أقلِب القنينة المتصلة حتى تصبح قنينة أدينوفيت بالأعلى. اسحب محلول<br />أدينويت إلى المحقن عن طريق سحب المكبس للخلف ببطء. افصل المحقن<br />عن القنينة. صِل إبرة التسريب إلى المحقن باستخدام مجموعة تسريب مجنحة<br />)ذات جناحين(، إذا كان ذلك متاحًا. وجّه الإبرة لأعلى وأزل أي فقاعات هوائية<br />بالضغط برفق بإصبعك على المحقن ودفع الهواء ببطء وبحرص خارج المحقن<br />والإبرة. يجب أن يبدو محلول أدينوفيت صافيًا وعديم اللون. وفي حال لم يكن<br />في الحال. Baxalta كذلك فيجب عليك إبلاغ<br />10 10 في حال كنت تستخدم أكثر من قنينة من أدينوفيت، فقد يتم سحب محتويات أكثر<br />من قنينة في نفس المحقنة<br />.) )اتبع الخطوات من 1 إلى 9<br />منفصل لمزج كل قنينة إضافية من BAXJECT II Hi-Flow قد تحتاج لجهاز<br />أدينوفيت. ضع عاصبة وجهز مكان الحقن وقم بمسح الجلد جيدًا بمسحة تحضير<br />كحولية معقمة )أو أي محلول مناسب آخر يقترحه مقدم الرعاية الصحية أو مركز<br />الهيموفيليا(.<br />11 11 أدخِل الإبرة داخل القنينة وانزع العاصبة. قم بالتسريب البَطيء للأدينوفيت. لا<br />تسرب بمعدل أكثر من 10 ملل في الدقيقة.<br />12 12 انزع الحقنة عن القنينة واستخدم قطعة شاش معقمة واضغط بها على مكان<br />التسريب لعدة دقائق.<br />13 13 لا تُعِد استخدام الأبرة. ضعها مع المحقنة المستخدمة في حاوية المواد الحادة<br />ذات الهيكل الصلب للتخلص منها بشكل سليم.<br />14 14 انزع الملصق القابل للإزالة من قنينة أدينوفيت وضعه في سجلك. نظِّف<br />9 أو : أي دماء منسكبة بمزيج مجهز حديثًا بنسبة مبيض إلى ماء تساوي 1<br />الصابون والماء أو أي محلول تعقيم منزلي.<br />معًا في BAXJECT II Hi-Flow 15 15 تخلَّص من القنينات المستعملة وجهاز<br />حاوية الأدوات الحادة ذات الهيكل الصلب. لا تتخلص من هذه اللوازم في<br />النفايات المنزلية العادية.<br />ما نقاط القوة في جرعة أدينوفيت؟<br />طريقة استخدام الدواء<br />يستخدم بعد التحضير فقط، عند الحقن الوريدي<br />التناول<br />&bull;افحص بالبصر محلول أدينوفيت المذاب لفحص اللون ووجود الجسيمات، متى<br />تسنى ذلك في المحلول والحاوية. يجب أن يكون محلول أدينوفيت النهائي صافيًا<br />وعديم اللون.<br />لا تستخدم الدواء إذا لاحظت وجود جسيمات أو تغيّر في اللون.<br />&bull;تناول أدينوفيت بأسرع وقت ممكن، وقبل مرور ثلاث ساعات من تحضيره.<br />٪ &bull;سترفع وحدة واحدة لكل كجم من وزن الجسم مستوى العامل الثامن بنسبة 2<br />وحدة دولية لكل ديسيلتر<br />)وحدة دولية لكل ديسيلتر(. يوضع ملصق تعريف على كل قنينة من أدينوفيت<br />وبه الكمية الفعلية من العامل الثامن<br />) المأشوب في كل وحدة دولية. ) 2.1<br />&bull;العلاج حسب الطلب والتحكم في نوبات النزيف إدارة الفترة المحيطة بالجراحة:<br />عدد الزيادة التقديرية للعامل الثامن )وحدة دولية \ ديسيلتر أو بنسبة مئوية من<br />2 )وحدة &times; ]) المستوى العادي( = ]الجرعة الكلية )وحدة دولية( \ وزن الجسم )كجم<br />دولية \ ديسيلتر لكل وحدة دولية \ كجم(<br />0.5 )وحدة دولية \ كجم لكل &times; ) عدد الجرعات )وحدة دولية( = وزن الجسم )كجم<br />وحدة دولية \ ديسيلتر(<br />50 وحدة دولية لكل كجم من وزن الجسم - &bull;علاج الوقاية الروتيني: تناول 40<br />مرتين في الأسبوع )ابدأ الجرعة بتناول 55 وحدة دولية لكل كجم من وزن<br />الجسم مرتين في الأسبوع للمرضى أقل من 12 عامًا وبحد أقصى 70 وحدة<br />دولية لكل كجم(.<br />&bull;الحقن عن طريق الوريد في وقت أقل من أو يساوي 5 دقائق )أقصى معدل<br />) للتسريب هو 10 ملل في الدقيقة(. ) 2.3<br />في حالة استخدام جرعة أكبر مما ينبغي من أدينوفيت<br />إذا كنت تعتقد أنك تناولت جرعة من أدينوفيت أكثر مما ينبغي، فتحدث إلى الطبيب<br />في أقرب وقت ممكن</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد تكون مصابًا بتفاعلات الحساسية من أدينوفيت. لذا؛ اتصل بمقدم الرعاية الصحية<br />في الحال، وأوقِف العلاج في حال حدوث طفح أو شرى أو حكة أو ضيق في الحلق<br />أو ألم أو ضيق بالصدر أو صعوبة التنفس أو الدوار أو الدوخة أو الغثيان أو الإغماء.<br />والآثار الجانبية الشائعة لأدينوفيت هي، الصداع والغثيان. أخبِر مقدم الرعاية الصحية<br />إذا كنت تشعر بأي آثار جانبية مزعجة أو مستمرة.<br />هذه ليست جميع الآثار الجانبية الممكنة لعقار أدينوفيت. يمكنك طلب معلومات من<br />مقدم الرعاية والمكتوبة خصيصًا لأخصائيي الرعاية الصحية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تجمِّد المنتج.<br />&bull;يُخزن في الثلاجة في درجة حرارة تتراوح بين 2 درجة مئوية إلى 8 درجات<br />مئوية<br />&bull;يمكن أن يُحفظ في درجة حرارة الغرفة والتي لا تتعدى 30 درجة مئوية لمدة<br />تصل لثلاثة أشهر.<br />اكتب التاريخ على العبوة عند إخراج أدينوفيت من الثلاجة. ◦<br />بعد تخزينه في درجة حرارة الغرفة، لا تُعِد المنتج مرة أخرى إلى ◦<br />الثلاجة.<br />&bull;لا تستخدم الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة والقنينة.<br />&bull;خزِّن أدينوفيت في العلبة الأصلية ولا تعرِّضه لضوءٍ شديد.<br />&bull;يجب إستعمال المحلول المخفف بعد فتح العبوة في مدة لا تتجاوز الثلاث<br />ساعات في درجة حرارة الغرفة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أ.ما محتويات أدينوفيت<br />- -المادة الفعالة هي، عامل مضاد الناعور )المأشوب(، بلمرة غليكول البولي<br />إيثيلين<br />- -المكونات الأخرى هي:تريس ومانيتول وطرهالوز وجلوتاثيون و/أو<br />بوليسوربات 80<br />- - المذيب عبارة عن مياه معقمة<br />في BAXJECT III يأتي أدينوفيت مع 5 ملل من المياه المعقمة للحقن في نظام<br />سبعة تركيزات مختلفة من الجرعات: 250 وحدة دولية )وحدة دولية( 500 وحدة<br />دولية و 750 وحدة دولية و 1000 وحدة دولية سيُطبع التركيز الفعلي على الملصق<br />التعريفي وعلى العبوة. سيتم ترميز التركيزات السبعة لونيًا على النحو التالي:<br />سيوضع ملصق تعريفي على كل قنينة من أدينوفيت به نشاط العامل المضاد للناعور<br />والمبين في الوحدة الدولية لكل قنينة.<br />أزرق فاتح تركيز الجرعة تقريبيًا هو 250 وحدة دولية لكل قنينة<br />وردي تركيز الجرعة تقريبًا هو 500 وحدة دولية لكل قنينة<br />أخضر فاتح تركيز الجرعة تقريبًا هو 1000 وحدة دولية لكل قنينة<br />ما شكل أدينوفيت وما محتويات العبوة<br />معقم ومضاد للحمى ومسحوق أبيض يقترب من الأبيض المائل للصفرة. ينبغي أن<br />يبدو المحلول بعد تجهيزه صافيًا وعديم اللون وخاليًا من الجسيمات الغريبة.<br />قد لا تتوفر جميع العروض في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>-----</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك تصريح التسويق<br />Baxalta US Inc.*<br />300 shire way, Lexington, MA 02421, USA<br />Tel: +1 617-349-0200<br />* شركة فرعية مملوكة بالكامل لشركة تاكيدا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر عام 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ADYNOVATE 500 IU / 5 ml powder and solvent for solution for injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial label of ADYNOVATE states the nominal factor VIII potency in international units.
ADYNOVATE, Antihemophilic Factor (Recombinant), PEGylated, is formulated as a sterile, non-pyrogenic,
white to off-white powder for intravenous injection and is supplied in single-use vials containing nominal
(approximate) potencies of 250, 500 or 1000, International Units (IU).
ADYNOVATE is a recombinant full-length human coagulation factor VIII (2,332 amino acids with a
molecular weight [MW] of 280 kDa) covalently conjugated with one or more molecules of polyethylene
glycol (MW 20 kDa). The therapeutic activity of ADYNOVATE is derived from its parent drug substance,
ADVATE [Antihemophilic Factor (Recombinant)], which is produced by recombinant DNA technology from
the Chinese hamster ovary cell line. The ADVATE molecule is then covalently conjugated with the
polyethylene glycol, which targets lysine residues. The cell culture, pegylation, purification process and
formulation used in the manufacture of ADYNOVATE do not use additives of human or animal origins. The
PEG moiety is conjugated to the rAHF (ADVATE) to increase the plasma half-life through the reduction of
the LRP-1 receptor-mediated clearance of the FVIII molecule.
The powder for injection is reconstituted with 5 mL sterile water for injection.
ADYNOVATE contains no preservative.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection.
Powder: White to off-white friable powder.
Solvent: Clear and colorless solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ADYNOVATE, Antihemophilic Factor (Recombinant), PEGylated, is a human antihemophilic factor<br />indicated in children and adults with hemophilia A (congenital factor VIII deficiency) for:<br />- On-demand treatment and control of bleeding episodes<br />- Perioperative management<br />- Routine prophylaxis to reduce the frequency of bleeding episodes<br />Limitation of Use<br />ADYNOVATE is not indicated for the treatment of von Willebrand disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For intravenous use after reconstitution only.<br />&bull; Each vial label of ADYNOVATE states the actual factor VIII potency in international units. This may be<br />more or less than the nominal vial potency/content. One international unit corresponds to the activity of factor<br />VIII contained in one milliliter of normal human plasma.<br />&bull; Dosage and duration of treatment depend on the severity of factor VIII deficiency, the location and extent of<br />the bleeding, and the patient&rsquo;s clinical condition. Careful monitoring of replacement therapy is necessary in<br />cases of serious or life-threatening bleeding episodes.<br />&bull; Potency assignment is determined using a one-stage clotting assay. Plasma factor VIII levels can be<br />monitored clinically using a one-stage clotting assay.<br />&bull; Calculate the dose of ADYNOVATE based on the empirical finding that one international unit of<br />ADYNOVATE per kg body weight increases the plasma factor VIII level by 2 IU per dL of plasma. Use the<br />following formula to estimate the expected in vivo peak increase in factor VIII level expressed as IU per dL<br />(or % of normal) and the dose to achieve a desired in vivo peak increase in factor VIII level:<br />Estimated Increment of factor VIII (IU/dL or % of normal) = [Total Dose (IU)/body weight (kg)] x 2 (IU/dL<br />per IU/kg)<br />Dose (IU) = Body Weight (kg) x Desired factor VIII Rise (IU/dL or % of Normal) x 0.5 (IU/kg per IU/dL)<br />&bull; Patients vary in their pharmacokinetic (e.g., clearance, half-life, in vivo recovery) and clinical response.<br />Base the dose and frequency of ADYNOVATE on the individual clinical response.<br />On-demand Treatment and Control of Bleeding Episodes<br />A guide for dosing of ADYNOVATE for the on-demand treatment and control of bleeding episodes is<br />provided in Table 1. Maintain plasma factor VIII activity level at or above the described plasma levels (in IU<br />per dL or % of normal).<br />Perioperative Management<br />A guide for dosing ADYNOVATE during surgery (perioperative management) is provided in Table 2.<br />Consideration should be given to maintain a factor VIII activity at or above the target range.<br />Type of bleeding Target Factor<br />VIII level<br />( % of normal<br />or IU/dL)<br />Dose*<br />(IU/kg)<br />Frequency of dosing<br />(hours)<br />Duration of<br />therapy<br />Minor<br />Including tooth extraction<br />60-100<br />30-50<br />Within one hour<br />before surgery.<br />Repeat after 24 hours<br />if necessary<br />Single dose or<br />repeat as needed<br />until bleeding is<br />resolved<br />Major<br />Intracranial, intra-abdominal, 80-120 40-60 Within one hour Until adequate<br />or intrathoracic surgery, joint (pre- and before the operation wound healing<br />replacement surgery postoperative) to achieve 100%<br />activity.<br />Repeat every 8 to 24<br />hours (6 to 24<br />hours for patients<br />&lt;12 years of age)<br />to maintain FVIII<br />activity within the<br />target range<br />Type of bleeding Target Factor VIII<br />level<br />(IU/dl or % of normal)<br />Dose*<br />(IU/kg<br />)<br />Frequency of<br />dosing (hours)<br />Duration of<br />therapy<br />Minor<br />Early hemarthrosis, mild muscle<br />bleeding, or mild oral bleeding<br />episode.<br />20-40<br />10-20<br />12-24<br />Until bleeding is<br />resolved<br />Moderate<br />Muscle bleeding, moderate bleeding<br />into the oral cavity, definite<br />hemarthroses, and known trauma.<br />30-60<br />15-30<br />12-24<br />Until bleeding is<br />resolved<br />Major<br />Significant gastrointestinal bleeding,<br />intracranial, intra-abdominal or<br />intrathoracic bleeding, central nervous<br />system bleeding, bleeding in the<br />retropharyngeal or retroperitoneal<br />spaces or iliopsoas sheath, fractures,<br />head trauma.<br />60-100<br />30-50<br />8-24<br />Until bleeding is<br />resolved<br />Routine Prophylaxis<br />Administer 40-50 IU per kg body weight 2 times per week in children and adults (12 years and older).<br />Administer 55 IU per kg body weight 2 times per week in children (&lt;12 years) with a maximum of 70 IU per<br />kg. Adjust the dose based on the patient&rsquo;s clinical response.<br />Method of Administration<br />ADYNOVATE is for intravenous use.<br />ADYNOVATE should be administered at room temperature not more than 3 hours after reconstitution.<br />For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ADYNOVATE is contraindicated in patients who have had prior anaphylactic reaction to
ADYNOVATE, to the parent molecule (ADVATE), mouse or hamster protein, or excipients of
ADYNOVATE (e.g. Tris, mannitol, trehalose, glutathione, and/or polysorbate 80).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity:<br />Hypersensitivity reactions are possible with ADYNOVATE. Allergic-type hypersensitivity reactions,<br />including anaphylaxis, have been reported with other recombinant antihemophilic factor VIII<br />products, including the parent molecule, ADVATE. Early signs of hypersensitivity reactions that can<br />progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, and<br />pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity<br />reactions occur.<br />&bull; Neutralizing Antibodies:<br />Formation of neutralizing antibodies (inhibitors) to factor VIII can occur following administration of<br />ADYNOVATE. Monitor patients regularly for the development of factor VIII inhibitors by<br />appropriate clinical observations and laboratory tests. Perform an assay that measures factor VIII<br />inhibitor concentration if the plasma factor VIII level fails to increase as expected, or if bleeding is<br />not controlled with expected dose<br />&bull; Monitoring Laboratory Tests:<br />&bull; Monitor plasma factor VIII activity by performing a validated one-stage clotting assay to confirm<br />the adequate factor VIII levels have been achieved and maintained.<br />&bull; Monitor for the development of factor VIII inhibitors. Perform the Bethesda inhibitor assay to<br />determine if factor VIII inhibitor is present. If expected factor VIII activity plasma levels are not<br />attained, or if bleeding is not controlled with the expected dose of ADYNOVATE, use Bethesda<br />Units (BU) to determine inhibitor levels.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed with ADYNOVATE.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no data with ADYNOVATE use in pregnant women to inform a drug-associated risk.<br />Animal reproduction studies have not been conducted with ADYNOVATE. It is unknown whether<br />ADYNOVATE can cause fetal harm when administered to a pregnant woman or can affect reproduction<br />capacity. ADYNOVATE should be given to a pregnant woman only if clearly needed. In the U.S. general<br />population, the estimated background risk of major birth defect and miscarriage in clinically recognized<br />pregnancies is 2-4% and 15-20%, respectively.<br />Lactation<br />There is no information regarding the presence of ADYNOVATE in human milk, the effect on the breastfed<br />infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be<br />considered along with the mother&rsquo;s clinical need for ADYNOVATE and any potential adverse effects on the<br />breastfed infant from ADYNOVATE or from the underlying maternal condition.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ADYNOVI has no influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common adverse reactions (&ge;1% of subjects) reported in the clinical studies were headache and<br />nausea.<br />Clinical Trials Experience<br />Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the<br />clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not<br />reflect the rates observed in practice.<br />The safety of ADYNOVATE was evaluated in 237 previously treated patients (PTPs) and 6 previously<br />untreated patients (PUPs) with severe hemophilia A (factor VIII less than 1% of normal), who received at<br />least one dose of ADYNOVATE in 3 completed multi-center, prospective, open label clinical studies and 4<br />ongoing clinical studies. The median duration of participation per subject was 401 (min-max: 3-1034) days<br />and the median number of exposure days to ADYNOVATE per subject was 111 (min-max: 1-322). Table 3<br />lists the adverse reactions reported during clinical studies.<br />Immunogenicity<br />The risk of the development of factor VIII inhibitors with the use of ADYNOVATE was evaluated in 3<br />completed and 4 ongoing clinical trials. Subjects consisted of adolescent and adult (n=148 with &ge;150 prior<br />EDs) and pediatric PTPs [(&lt;6 years of age with &ge;50 prior EDs (n=32), &ge;6 years of age with &ge;150 prior EDs<br />(n=57)], and pediatric PUPs (n=6). In 191 adult and pediatric PTPs who were treated for at least 50 exposure<br />days with ADYNOVATE, the factor VIII inhibitor frequency was 0 (95% CI of 0 to 0.019). One PUP subject<br />from an ongoing study, who received at least one infusion of ADYNOVATE, developed neutralizing<br />antibodies to factor VIII. Immunogenicity also was evaluated by measuring the development of binding IgG<br />and IgM antibodies against factor VIII, PEGylated (PEG)-factor VIII, PEG and Chinese hamster ovary<br />(CHO) protein using validated ELISA assays. The majority of subjects (238/243) with at least one infusion of<br />ADYNOVATE did not develop a persistent binding antibody response to any of these antigens. Twenty-eight<br />subjects in total showed pre-existing antibodies to factor VIII (n=3), PEG-factor VIII (n=25) and/or PEG<br />(n=3) prior to the first exposure to ADYNOVATE.<br />Thirteen subjects who tested negative at screening developed transient antibodies against factor VIII (n=6),<br />PEG-FVIII (n=8) at one or two consecutive study visits. Antibodies were transient and not detectable at<br />subsequent visits. Five subjects showed positive results for binding antibodies at study completion or at the<br />time of data cutoff. Binding antibodies that were detected prior to exposure to ADYNOVATE, that transiently<br />developed during the trial or were still detectable at study completion or data cutoff could not be correlated to<br />any impaired treatment efficacy or altered PK parameters. There was no causal relationship between observed<br />adverse events and binding antibodies except in one subject where a causal relationship cannot be ruled out<br />&minus; The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&minus; Please contact the relevant competent authority.<br />based on available data. No subject had pre-existing or treatment-emergent antibodies to CHO protein. The<br />detection of antibodies that are reactive to factor VIII is highly dependent on many factors, including: the<br />sensitivity and specificity of the assay, sample handling, timing of sample collection, concomitant<br />medications and underlying disease. For these reasons, comparison of the incidence of antibodies to<br />ADYNOVATE with the incidence of antibodies to other products may be misleading.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No symptoms of overdose with recombinant coagulation factor VIII have been reported.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antihaemorrhagics, blood coagulation factor VIII, ATC code: B02BD02.<br />Hemophilia A is a disorder characterized by a deficiency of functional coagulation factor VIII, resulting in a<br />prolonged, patient plasma clotting time as measured by the activated partial thromboplastin time (aPTT).<br />Treatment with ADYNOVATE normalizes the aPTT over the effective dosing period. The administration of<br />ADYNOVATE increases plasma levels of factor VIII and can temporarily correct the coagulation defect in<br />hemophilia A patients.<br />Original Safety and Efficacy Clinical Trial<br />The safety, efficacy, and PK of ADYNOVATE were evaluated in a multicenter, open-label, prospective, nonrandomized,<br />two-arm clinical trial that compared the efficacy of a twice weekly prophylactic treatment<br />regimen to on-demand treatment and determined hemostatic efficacy in the treatment of bleeding episodes. A<br />total of 137 male PTPs (12 to 65 years of age) with severe hemophilia A received at least one infusion with<br />ADYNOVATE. Twenty-five of the 137 subjects were adolescents (12 to less than 18 years of age).<br />Subjects received either prophylactic treatment (n = 120) with ADYNOVATE at a dose of 40-50 IU per kg<br />twice weekly or on-demand treatment (n = 17) with ADYNOVATE at a dose of 10-60 IU per kg for a 6-<br />month period. The mean (SD) dose per prophylaxis infusion was 44.4 (3.9) IU per kg with a median dosing<br />interval of 3.6 days. There were 91 out of 98 (93%) subjects previously treated prophylactically prior to<br />enrollment, who experienced a reduction in dosing frequency during routine prophylaxis in the trial, with a<br />median reduction of 33.7% (approximately one more day between doses). One hundred eighteen of 120<br />(98%) prophylaxis subjects remained on the starting recommended regimen without dose adjustment, and 2<br />subjects increased their dose to 60 IU/kg during prophylaxis due to bleeding in target joints.<br />On-demand Treatment and Control of Bleeding Episodes<br />A total of 518 bleeding episodes were treated with ADYNOVATE in the per-protocol population, i.e. dosed<br />according to the protocol specific dosing requirements. Of these, 361 bleeding episodes (n=17 subjects)<br />occurred in the on-demand arm and 157 (n=61 subjects) occurred in the prophylaxis arm. The median dose<br />per infusion to treat all bleeding episodes in the per-protocol population was 29 (Q1: 20.0; Q3: 39.2) IU per<br />kg. The median dose per infusion to treat a minor, moderate, or severe/major bleeding episode in the perprotocol<br />population was 25.5 (Q1: 16.9; Q3: 37.6) IU/kg, 30.9 (Q1: 23.0; Q3: 43.1) IU/kg, or 36.4 (Q1: 29.0;<br />Q3: 44.5)IU/kg, respectively.<br />Routine Prophylaxis<br />A total of 120 subjects (treated population) received a twice a week regimen in the prophylaxis arm, and an<br />additional 17 subjects were treated episodically in the on-demand arm. In the treated population, the median<br />[mean] annualized bleed rate (ABR) in the on-demand treatment arm was 41.5 [40.8] compared to 1.9 [4.7]<br />while on a twice a week prophylaxis regimen (Table 6). In the per-protocol population, the median [mean]<br />annualized bleed rate (ABR) in the on-demand treatment arm was 41.5 [40.8] compared to 1.9 [3.7] while on<br />a twice a week prophylaxis regimen. Using a negative binomial model to estimate the ABR, there was a<br />significant reduction in the ABR (p &lt;0.0001) for subjects in the prophylaxis arm compared to the on-demand<br />arm.<br />In the treated population, the median [mean] ABR for the 23 adolescent subjects age 12 to &lt;18 years of age<br />on routine prophylaxis was 2.1 [5.2] compared to a median [mean] ABR of 1.9 [4.6] for the 97 subjects 18<br />years and older. Reduction in ABR between the treatment arms was observed regardless of baseline<br />subgroups examined, including age, presence or absence of target joints, and pre-trial treatment regimen. The<br />majority of the bleeding episodes during prophylaxis (95%) were of minor/moderate severity. Forty-five out<br />of 120 subjects (38%) experienced no bleeding episodes and 68 out of 120 subjects (57%) experienced no<br />joint bleeding episodes in the prophylaxis arm. Of those subjects who were compliant to regimen (perprotocol<br />population), 40 out of 101 subjects (40%) experienced no bleeding episodes. All subjects in the ondemand<br />arm experienced a bleeding episode, including a joint bleeding episode.<br />Routine Prophylaxis Clinical Trial in Pediatric Subjects (&lt;12 years of age)<br />The safety and efficacy of ADYNOVATE was evaluated in a total of 73 pediatric PTPs with severe<br />hemophilia A, of which 66 subjects were dosed (32 subjects aged &lt;6 years and 34 subjects aged 6 to &lt;12<br />years) in a separate pediatric clinical trial. The prophylactic regimen was 40 to 60 IU/kg of ADYNOVATE<br />twice a week, with a mean (SD) dose of 51.1 IU/kg. The median [mean] overall ABR was 2.0 [3.61] for the<br />66 subjects in the treated population and the median [mean] ABRs for spontaneous and joint bleeding<br />episodes were both 0. Of the 66 subjects treated prophylactically, 25 (38%) experienced no bleeding episodes,<br />44 (67%) experienced no spontaneous bleeding episodes, and 48 (73%) experienced no joint bleeding<br />episodes.<br />Of the 70 bleeding episodes observed during the pediatric trial, 82.9% were controlled with 1 infusion and<br />91.4% were controlled with 1 or 2 infusions. Control of bleeding was rated excellent or good in 63 out of 70<br />(90%) bleeding episodes. The definitions of excellent or good in the pediatric clinical trial were unchanged as<br />compared to the previously conducted prophylaxis clinical trial in adolescent and adult subjects.<br />Perioperative Management Clinical Trial<br />Eleven major surgical procedures (3 knee replacements, 2 arthroscopic synovectomies, 1 cyst extirpation, 1<br />port placement, 1 gastric band placement, and 3 multiple tooth extractions including 1 radicular cyst removal)<br />and 4 additional minor surgeries (1 synoviorthesis, 1 radiosynovectomy, 1 tooth extraction, 1 dermatological<br />surgery) were performed in 15 subjects. The preoperative loading dose ranged from 36 IU/kg to 99 IU/kg<br />(median: 65 IU/kg) and the total postoperative dose ranged from 177 IU/kg to 769 IU/kg (median: 305<br />IU/kg). The median total dose for major surgeries was 362 IU/kg (range: 237-863 IU/kg) and the median total<br />dose for minor surgeries was 97 IU/kg (range: 73-119 IU/kg).<br />Perioperative hemostatic efficacy was rated as excellent (blood loss less than or equal to that expected for the<br />same type of procedure performed in a non-hemophilic patient, and required blood components for<br />transfusions less than or similar to that expected in non-hemophilic population) for all 15 (11 major, 4 minor)<br />procedures. The median (QR) observed intraoperative blood loss (n=10) was 10.0 (Q1: 5.0, Q3: 50.0) mL<br />compared to the predicted average blood loss (n=11) of 50.0 (Q1: 6.0, Q3: 150.0) mL for major surgeries</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics (PK) of ADYNOVATE were evaluated in a multi-center, prospective, open label<br />clinical trial and compared with ADVATE in 26 subjects prior to initiation of prophylactic treatment with<br />ADYNOVATE and in 22 subjects after 6 months of treatment with ADYNOVATE. A single dose of 45<br />IU/kg was utilized for both products. The PK parameters, as shown in Table 4, were based on plasma<br />coagulation factor VIII activity measured by the one-stage clotting assay and are presented by age groups.<br />Incremental recovery was comparable between both products. The PK parameters determined after 6 months<br />of prophylactic treatment with ADYNOVATE were consistent with<br />the initial parameter estimates.<br />Pediatric Pharmacokinetics<br />Pharmacokinetic parameters calculated from 39 subjects &lt;18 years of age (intent-to-treat analysis) are<br />available for 14 children (2 to &lt;6 years), 17 older children (6 to &lt;12 years) and 8 adolescent subjects (12 to<br />&lt;18 years of age), as shown in Table 4. The mean clearance (based on body weight) of ADYNOVATE was<br />higher and the mean half-life was lower in children &lt;12 years of age than adults. A dose adjustment may be<br />required in children &lt;12 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Long-term studies in animals to evaluate the carcinogenic potential of ADYNOVATE or studies to determine<br />the effects of ADYNOVATE on genotoxicity or fertility have not been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Stabilizer and Excipient 5ml<br />Reconstitution<br />Target (per ml)<br />Tris(hydroxymethyl)aminomethane 1.22 mg<br />Calcium chloride 0.24mg<br />Mannitol 32 mg<br />Sodium chloride 5.26 mg<br />Trehalose dihydrate 8 mg<br />Glutathione 0.08 mg<br />Histidine 1.56 mg<br />Polysorbate 80 0.10 mg<br />Solvent:<br />Sterilized water for injection 5 ml</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal<br />products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial
2 years.
Before opening the product may be stored at room temperature (up to 30 °C) for a period of up to 3 months.
The end of the 3-month storage at room temperature should be recorded on the product carton. This date
should never exceed the one initially mentioned on the outer carton. At the end of this period the product shall
not be put back in the refrigerator, but shall be used or discarded.
After reconstitution
Chemical and physical in-use stability has been demonstrated for 3 hours at a temperature not above 30 °C.
From a microbiological point of view, unless the method of reconstitution precludes the risk of microbial
contamination, the product should be used immediately. If not used immediately, in-use storage times and
conditions are the responsibility of the user. Do not refrigerate.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store ADYNOVATE in powder form refrigerated (2&deg;C to 8 &deg;C). Do not freeze.<br />ADYNOVATE with BAXJECT II Hi-Flow device: Keep the vial in the outer carton in order to protect from<br />light.<br />For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I glass vial, closed with a chlorobutyl rubber stopper, containing 250 IU, 500 IU or 1000 IU of powder.<br />Type I glass vial, closed with a chlorobutyl rubber stopper, containing 5 ml of sterilized water for injections.<br />The medicinal product is provided the following configuration:<br />- ADYNOVATE with BAXJECT II Hi-Flow device: Each pack contains a powder vial, a solvent vial and a<br />device for reconstitution (BAXJECT II Hi-Flow).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preparation<br />&bull; Do not remove ADYNOVATE or diluent vials from the external housing.<br />&bull; Examine the packaging containing ADYNOVATE to ensure no damage or peeling of the lid is evident. Do<br />not use if the lid is not completely sealed on the blister.<br />&bull; Use aseptic technique (clean and germ free) and a flat work surface during the reconstitution procedure.<br />Reconstitution<br />1. Allow the vials of ADYNOVATE and diluent to reach room temperature before use.<br />2. Remove plastic caps from the ADYNOVATE and diluent vials.<br />3. Cleanse rubber stoppers with a sterile alcohol prep pad and allow to dry prior to use.<br />4. Open the BAXJECT II Hi-Flow device package by peeling away the lid, without touching the inside<br />(Figure A). Do not remove the device from the package.<br />Figure A<br />5. Turn the package over. Press straight down to fully insert the clear plastic spike through the diluent vial<br />stopper (Figure B).<br />Figure B<br />6. Grip the BAXJECT II Hi-Flow package at its edge and pull the package off the device (Figure C). Do not<br />remove the blue cap from the BAXJECT II Hi-Flow device. Do not touch the exposed purple plastic spike.<br />Figure C<br />7. Turn the system over so that the diluent vial is on top. Quickly insert the purple plastic spike fully into the<br />ADYNOVATE vial stopper by pushing straight down (Figure D). The vacuum will draw the diluent into the<br />ADYNOVATE vial.<br />Figure D<br />8. Swirl gently until ADYNOVATE is completely dissolved. Do not refrigerate after reconstitution.<br />9. If the dose requires more than one vial of ADYNOVATE, reconstitute each vial using the above steps. Use<br />a different BAXJECT II Hi-Flow device to reconstitute each vial of ADYNOVATE and diluent.<br />Administration<br />&bull; Visually inspect the reconstituted ADYNOVATE solution for particulate matter and discoloration prior to<br />administration, whenever solution and container permit. The final ADYNOVATE solution should be clear<br />and colorless. Do not use if particulate matter or discoloration is observed.<br />&bull; Administer ADYNOVATE as soon as possible, but no later than 3 hours after reconstitution.<br />Administration Steps:<br />1. Remove the blue cap from the BAXJECT II Hi-Flow device. Connect the syringe to the BAXJECT II Hi-<br />Flow device (Figure E). Use of a Luer-lock syringe is recommended. Do not inject air.<br />Figure E<br />2. Turn the system upside down (ADYNOVATE vial now on top). Draw the factor concentrate into the<br />syringe by pulling the plunger back slowly<br />(Figure F).<br />Figure F<br />3. If a patient is to receive more than one vial of ADYNOVATE, the contents of multiple vials may be drawn<br />into the same syringe.<br />4. Disconnect the syringe; attach a suitable needle.<br />5. Inject ADYNOVATE intravenously over a period of less than or equal to 5 minutes (maximum infusion<br />rate 10 mL per min).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Baxalta US Inc. "A wholly owned subsidiary of
Takeda Pharmaceutical Company Limited"
300 Shire way, Lexington, MA 02421, USA
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                This SPC is last revised in September 2018.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>